secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2026-08-05T20:11:23+00:00
Accession:  0001104659-26-091099
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q2 net income $162.8M; ICOTYDE launch, rusfertide PDUFA in Aug 2026
-------------------------------------------------------------------------------

- Q2 2026 net income $162.8M ($2.47 basic EPS) vs net loss $34.8M in Q2 2025; revenue $213.5M from Takeda opt-out and J&J milestones.
- ICOTYDE (icotrokinra) first full quarter of commercial sales; FDA approved Mar 2026; J&J partnership with up to $580M milestones and 6-10% royalties.
- Rusfertide NDA under priority review for polycythemia vera; PDUFA date Aug 2026; Takeda opt-out triggered $200M payment, additional $200M and $75M upon approval.
- PN-881 (oral IL-17 antagonist) Phase 2b psoriasis program planned early Q1 2027; PN-477sc (triple agonist) Phase 1 initiated.
- Cash $849.5M as of June 30, 2026; potential share buyback program announcement by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/0001104659-26-091099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer